*Available online* www.ijpras.com

International Journal of Pharmaceutical Research & Allied Sciences, 2025, 14(3):64-72
https://doi.org/10.51847/j1CJ5gdQVa


Original Article

ISSN : 2277-3657
CODEN(USA) : IJPRPM

# *Managing Biopharmaceutical Variability without Demanding Manufacturing Sameness through Lifecycle Evidence, Process Understanding, Change Control, and Product Evolution*

**Luca Ferraro[1]*, Matteo Ricci[1], Giulia Moretti[2], Paolo Greco[3]**

*[1] Department of Biopharmaceutical Variability and Lifecycle, Faculty of Pharmacy, University of Bologna, Bologna, Italy.*
*[2] Department of Process Understanding and Change Control, Faculty of Pharmacy, University of Turin, Turin, Italy.*
*[3] Department of Product Evolution and Manufacturing, Faculty of Pharmacy, Sapienza University of Rome, Rome, Italy.*

***Email:** luca.ferraro@unibo.it*

## ABSTRACT

*Biopharmaceuticals are heterogeneous products whose molecular distributions may vary across batches, manufacturing sites, process states, storage periods, analytical platforms, and delivery configurations. Lifecycle assurance should therefore focus less on preserving historical manufacturing sameness and more on determining whether product evolution remains compatible with clinically relevant quality, safety, efficacy, exposure, and immunogenicity expectations. This article proposes a non-empirical Lifecycle Variability-Control Architecture that integrates product-state knowledge, process understanding, critical quality attributes, longitudinal monitoring, manufacturing-change comparability, change-impact assessment, evidence escalation, and governance. The architecture distinguishes inherent heterogeneity from uncontrolled variability, transient excursions from directional drift, analytical difference from functional consequence, and functional consequence from clinically meaningful difference. Manufacturing modifications are evaluated through a proposed pathway linking process perturbation to product attributes, biological function, pharmacokinetics, pharmacodynamics, immunogenicity, administration, and plausible clinical consequence. Evidence is escalated according to residual uncertainty and method sensitivity rather than change magnitude alone. Product evolution without loss of clinical continuity is framed as a bounded, traceable conclusion rather than proof of molecular identity, interchangeability, automatic substitution, or universal indication extrapolation. Governance responsibilities include maintenance of product knowledge, assay qualification, model oversight, independent challenge, escalation decisions, and post-change learning. The architecture is an original conceptual synthesis that requires prospective analytical, manufacturing, computational, clinical-pharmacology, immunogenicity, and implementation validation. It does not define universal variability limits, predict clinical outcomes, prescribe regulatory decisions, or establish deployment readiness.*

**Key words:** *Biopharmaceuticals, Biosimilars, Comparability, Analytical similarity, Immunogenicity, Interchangeability*

**Received:** 10 April 2025; **Revised:** 14 August 2025; **Accepted:** 18 August 2025

## INTRODUCTION

Biopharmaceutical quality cannot be represented adequately as preservation of one fixed molecular state. Recombinant proteins and related biological products are manufactured as distributions of molecular forms whose

observed profiles depend on biological expression, purification, formulation, storage, delivery, and analytical capability. Biosimilar frameworks demonstrate that assurance can be constructed through comparative evidence and reduction of clinically relevant uncertainty rather than proof of complete molecular identity [1].

The manufacturing process is a controlled means of producing the product, not the therapeutic product itself. Lifecycle continuity therefore does not require every historical raw material, operating condition, analytical platform, site, scale, device, or container configuration to remain unchanged. Evidence should instead address the uncertainty created by a particular change. Residual uncertainty offers a more coherent basis for evidence selection than automatic repetition of a fixed analytical or clinical package [2].

Clinical evidence must also be selected for sensitivity to the question being asked. Comparative efficacy studies may be poorly suited to detecting subtle product-related differences when endpoints are variable, background therapies are influential, or analytical and clinical-pharmacology evidence has already resolved the suspected mechanism. Data-driven assessment of biosimilar monoclonal-antibody programs supports tailoring clinical development according to the contribution expected from additional evidence [3].

This Original Lifecycle-Control Architecture Article proposes a Lifecycle Variability-Control Architecture, or LVCA, that integrates product heterogeneity, process understanding, critical quality attributes, longitudinal monitoring, comparability, evidence escalation, clinical continuity, and governance. The framework is proposed rather than validated. It does not define regulator-approved pathways, universal limits, clinical recommendations, or evidence waivers.

*Inherent heterogeneity of biological products*

Biopharmaceutical heterogeneity is generated by the biology and physicochemistry of production. Product populations may include glycoforms, charge variants, size variants, terminal-processing states, conformational states, oxidized forms, deamidated forms, and other molecular species. Longitudinal analyses of trastuzumab lots have shown movement in antibody-dependent cellular cytotoxicity-related attributes, illustrating that a marketed reference profile need not remain stationary throughout its lifecycle [4].

Heterogeneity also begins upstream. Host-cell selection affects glycosylation machinery, precursor availability, intracellular processing, and the relative abundance of glycan structures [5]. Culture conditions, nutrient state, harvest timing, downstream processing, storage, and formulation may further influence product distributions. Some variability is intrinsic to the expression system, while other variability is process-responsive and potentially controllable.

The importance of heterogeneity depends on its relationship to function. Post-translational modifications and immunoglobulin subclass can influence Fc-receptor binding, complement activation, half-life, and effector activity [6]. The same molecular change may therefore have different significance across products, depending on mechanism of action, formulation, route, exposure, and intended clinical use.

LVCA treats heterogeneity as a product-state property that must be characterized, explained, and monitored. It separates three questions: which forms are present, why their distributions change, and whether the change can plausibly affect performance. Inherent heterogeneity does not make every variation acceptable, but neither does analytical detectability make every difference clinically important.

*Variability, drift, and clinically meaningful difference*

Variability is defined as observed variation across molecules, batches, process states, sites, scales, storage intervals, presentation formats, analytical methods, or time. Analytical similarity compares multidimensional structural, physicochemical, and functional characteristics. It does not assert molecular identity. Evaluation of the adalimumab biosimilar SB5 illustrates how similarity conclusions are assembled across multiple quality attributes and orthogonal methods [7].

Comparability addresses a different question: whether a manufacturing change is expected to affect product quality, safety, or efficacy. Manufacturing modifications are common across approved monoclonal antibodies and Fc-fusion proteins, but the supporting evidence varies with the product and the change [8]. Comparability should therefore not be conflated with biosimilarity, which concerns comparison with another sponsor's reference product.

Drift is proposed as persistent or directional movement in a joint product-attribute or process-state distribution relative to a justified baseline. A single excursion, method transition, reference-standard change, or isolated process alarm does not establish drift. Conversely, individual results may remain within specification while

several attributes move together. Structural and functional evaluation of rituximab products demonstrates why analytical observations require orthogonal functional interpretation [9].

A clinically meaningful difference is a difference with a plausible and sufficiently material consequence for efficacy, safety, exposure, immunogenicity, administration, or another clinically relevant aspect of use. LVCA therefore proposes an acceptable variability envelope: a product-specific, multidimensional, time-indexed, and evidence-conditioned representation of product and process variation compatible with current clinical-continuity assumptions. It is not a universal numerical range, a substitute for specifications, or proof that all variation inside the envelope is harmless.

*Proposed lifecycle-control architecture*

The LVCA is based on the principle that evidence should be tailored to unresolved uncertainty. Biosimilar-development scholarship supports selecting additional evidence according to what analytical, functional, pharmacokinetic, pharmacodynamic, and mechanistic studies have already established [10]. For lifecycle manufacturing control, this means that evidence should not be triggered solely by whether a modification appears operationally large or administratively major.

The architecture is designed as a learning system. Scientific principles for biosimilar evaluation have evolved as analytical technologies and clinical experience have accumulated [11]. Lifecycle control should likewise allow the product-knowledge state to be revised when attributes become better understood, assays improve, process relationships change, or post-change evidence challenges earlier assumptions.

LVCA contains four interacting layers. The product-state layer records heterogeneity, attribute distributions, analytical capability, reference standards, stability behavior, and CQA–function relationships. The process-state layer records material attributes, process parameters, unit-operation mechanisms, multivariate states, sensors, models, and control assumptions. The change-impact layer connects a manufacturing modification to possible process, attribute, functional, exposure, immunogenicity, administration, and clinical consequences. The evidence and governance layer determines what evidence is required, when escalation may stop, who challenges the rationale, and how findings update lifecycle knowledge. Evidence-based proposals for future biosimilar development support the general direction of this adaptive approach, but do not validate LVCA itself [12].

Three original constructs organize the architecture. The acceptable variability envelope defines the evidence-conditioned region of acceptable product and process variation. The residual-uncertainty checkpoint asks whether the evidence resolves the plausible consequence of the change. The evidence-stopping record documents why further testing is unlikely to add decision-relevant information. The selected literature supports stepwise reduction of residual uncertainty before additional clinical testing is chosen [1-3].

**Figure 1** presents the closed lifecycle loop connecting product and process knowledge, monitoring, change identification, change-impact assessment, evidence escalation, implementation, and post-change learning.



**Figure 1.** Lifecycle Control of Biopharmaceutical Variability.

*Process understanding and critical quality attributes*

Process understanding gives lifecycle evidence its causal structure. Release testing describes selected properties of a completed batch but may not explain why an attribute changed, whether it will recur, or which conditions require control. Real-time release testing therefore depends on reliable process–quality relationships and fit-for-purpose measurements [13].

Monitoring capability must match the scientific question. Spectroscopy, chromatography, mass spectrometry, automated sampling, sensor systems, and chemometric models differ in sensitivity, selectivity, frequency, calibration, and unit-operation suitability. No single platform observes every relevant process parameter or quality attribute [14]. Conclusions about stability or absence of drift are therefore limited by what the monitoring system can detect.

Critical quality attributes connect manufacturing control to possible pharmaceutical consequences, but criticality must be justified. Cross-product glycan profiles may provide context, yet they cannot replace product-specific evaluation of mechanism, function, exposure, route, formulation, and assay sensitivity [15]. An attribute may be controlled cautiously while its direct clinical relevance remains uncertain, but precautionary control should not be described as demonstrated clinical criticality.

LVCA proposes four process-understanding states: descriptive, where associations are observed; linked, where reproducible process–attribute relationships are established; predictive, where bounded forecasts are possible; and decision-qualified, where a model or relationship is validated for a defined lifecycle use. These are proposed organizational states, not validated maturity levels.

*Comparability after Manufacturing Change*

Comparability begins with a defined modification and an explicit consequence hypothesis. Comparator strategy may require bridging among lots, regions, manufacturing histories, or reference sources. The global-reference concept illustrates that scientifically justified bridging may connect evidence obtained with different physical comparator sources when their relationship is adequately established [16].

Presentation changes can create distinct evidence needs. Moving from a prefilled syringe to an autoinjector may alter delivery mechanics, injection conditions, or exposure even when the formulation is nominally unchanged. Pharmacokinetic bridging examples show that device changes can create knowledge gaps not resolved by formulation comparison alone [17].

A defensible comparability conclusion may integrate change-specific assessment, comparator strategy, and longitudinal product-consistency evidence [8, 16, 18]. Historical consistency is informative only when the monitored attributes and methods are capable of detecting the mechanism affected by the new modification.

**Table 1** summarizes the concepts and boundaries used by the architecture.

**Table 1.** Definitions, components, relationships, and intended uses in Managing Biopharmaceutical Variability without Demanding Manufacturing Sameness through.

| Component | Problem addressed | Proposed relationship or use | Evidence required | Principal boundary |
|---|---|---|---|---|
| **Inherent heterogeneity** | Biological products contain related molecular forms. | Product distributions are managed through product-state knowledge. | Longitudinal structural and functional characterization [4-6]. | Heterogeneity does not make all variation acceptable. |
| **Analytical similarity** | Comparative testing may be mistaken for identity. | Orthogonal evidence reduces uncertainty about product differences [7, 9]. | Qualified assays and representative lots. | Analytical similarity is not clinical equivalence. |
| **Comparability** | Manufacturing change must be linked to product consequence. | Evidence follows the change-specific mechanism [8, 16-18]. | Pre-change/post-change and process evidence. | Comparability is not biosimilarity or interchangeability. |
| **Critical quality attributes** | Measurable attributes differ in relevance. | CQA status is stored as revisable lifecycle knowledge. | Mechanistic and functional support [5, 6, 13-15]. | CQA designation is product-specific. |

| | | | | |
|---|---|---|---|---|
| **Drift** | Coordinated movement may remain within individual specifications. | Persistent joint-distribution movement triggers investigation. | Longitudinal and orthogonal evidence. | Drift does not establish clinical harm. |
| **Acceptable variability envelope** | Static specifications may not represent lifecycle knowledge. | **Proposed:** product-specific, evidence-conditioned variability region. | Prospective validation against known changes. | Not a universal numerical limit. |
| **Residual-uncertainty checkpoint** | Fixed evidence packages may over-test or under-test. | **Proposed:** escalation follows unresolved consequence. | Decision-impact and validation studies. | Does not waive scientific or regulatory requirements. |
| **Clinical continuity** | Product evolution must preserve expected performance. | **Proposed:** bounded lifecycle assurance conclusion. | Analytical, pharmacological, immunogenicity, and monitoring evidence. | Not proof of interchangeability or substitution. |

*Trending, monitoring, and multivariate control*

Biopharmaceutical manufacturing generates high-dimensional process data but relatively few batches. Monitoring models must therefore address small samples, correlated trajectories, missing values, process evolution, and overfitting [19]. Internal model performance is insufficient when the intended use involves release, comparability, or escalation decisions.

Machine-learning tools have been implemented for continued verification of chromatography operations, showing that multivariate methods can support detection of process-state changes in a defined context [20]. Such examples demonstrate feasibility, not transferability across products, sites, resins, scales, or control strategies.

Trending includes raw measurements, derived attributes, process trajectories, deviations, interventions, release results, analytical controls, and stability findings. Monitoring output should have an explicit role: descriptive surveillance, investigation support, prediction, direct control, or decision qualification. Signals outside that validated role should not be treated as decision evidence.

LVCA proposes multivariate surveillance of the joint product and process state. Potential drift should trigger analytical confirmation, investigation of process causes, reassessment of affected CQAs, and review of the acceptable variability envelope. A model alert does not prove product change, and absence of an alert does not prove absence of clinically relevant drift.

*Change-impact assessment and evidence escalation*

Evidence escalation should begin with the uncertainty left unresolved by analytical and process evidence. Comparative efficacy studies may add limited information when earlier evidence has already addressed the plausible mechanism and the clinical endpoint is comparatively insensitive [21]. This does not make such trials unnecessary in every case.

Sensitive pharmacodynamic markers may be more informative when they lie close to the affected mechanism. A randomized study using PCSK9 inhibitors illustrates how a mechanism-linked pharmacodynamic endpoint can address a defined similarity question [22]. The broader principle is that evidence types are not interchangeable.

The proposed change-impact pathway asks: what mechanism could the modification perturb, what consequence could follow, and which method is most sensitive to that consequence? Evidence may escalate through enhanced analytics, functional testing, process studies, pharmacokinetic bridging, pharmacodynamic assessment, immunogenicity evaluation, comparative clinical testing, or post-change monitoring.

Clinical evidence should be selected for sensitivity to the unresolved mechanism, with pharmacokinetics, pharmacodynamics, and comparative efficacy serving different uncertainty-reduction functions [3, 21, 22]. Evidence stopping requires explicit consideration of assay limitations, alternative pathways, rare or delayed effects, population dependence, reversibility, and the consequence of an incorrect decision.

**Table 2** converts the architecture into testable validation requirements.

**Table 2.** Testable propositions, evidence requirements, and validation criteria for Managing Biopharmaceutical Variability without Demanding Manufacturing Sameness through.

| Architecture stage | Core function | Validation criterion | Potential failure | Readiness boundary |
|---|---|---|---|---|
| **Product-state knowledge** | Maintain current understanding of heterogeneity and attribute relationships. | Reproducible characterization across representative lots and time. | Incomplete attribute coverage or unstable standards. | Descriptive knowledge is not decision qualification. |
| **Process-state understanding** | Connect materials and operations to product attributes. | Deliberate perturbation and reproducible process–attribute relationships. | Confounding or transfer beyond the studied domain. | Correlation is not causation. |
| **Longitudinal monitoring** | Detect coordinated or persistent movement. | Temporal validation, known-change detection, and orthogonal confirmation. | Overfitting, missing data, or false alarms. | Monitoring output alone cannot establish consequence. |
| **Change-impact chain** | Translate modification into plausible pharmaceutical effects. | Prospective testing across diverse change types. | Missing causal links or interacting attributes. | Proposed reasoning model, not validated causality. |
| **Residual-uncertainty checkpoint** | Determine whether escalation is required. | Independent reviewers reproduce the same unresolved questions. | Convenience-driven stopping or reflexive over-testing. | Does not guarantee regulatory acceptance. |
| **PK or PD escalation** | Resolve exposure- or mechanism-proximal uncertainty. | Sensitive, relevant, reproducible endpoints. | Insensitive biomarker or exposure confounding. | Does not answer every efficacy or immunogenicity question. |
| **Comparative clinical escalation** | Address unresolved clinically testable consequences. | Endpoint and population sensitive to the hypothesized difference. | Noisy endpoints or masking by background treatment. | A negative trial cannot compensate for insensitive design. |
| **Evidence-stopping record** | Document why further evidence is unlikely to change the decision. | Traceable rationale confirmed through independent challenge. | Cost-saving assertion substituted for science. | Must be revisited when new evidence emerges. |
| **Post-change learning** | Update knowledge after implementation. | Predefined monitoring and timely reassessment. | Fragmented ownership or delayed signal review. | Does not replace necessary pre-change evidence. |

*Product evolution without loss of clinical continuity*

Clinical continuity is the justified expectation that product evolution has not materially altered performance relevant to intended use. Switching studies are informative because they assess efficacy, safety, and immunogenicity after movement between reference products and biosimilars [23]. Their relevance to internal manufacturing change is indirect and should not be overstated.

Interchangeability remains distinct. Depending on jurisdiction, it may carry legal, prescribing, substitution, or evidentiary consequences beyond biosimilarity or comparability [24]. Clinical continuity must therefore not be used as a synonym for interchangeability.

Longitudinal consistency supports clinical-continuity assessment by showing that attribute distributions remain controlled across commercial history [18]. It cannot exclude an unmeasured change, delayed stability effect, rare immunogenicity pathway, or device-related consequence.

LVCA proposes a clinical-continuity record that states what has been demonstrated, inferred, left uncertain, and assigned to post-change monitoring. It is a bounded lifecycle conclusion, not proof of molecular identity, automatic substitution, repeated-switching acceptability, or universal indication extrapolation.

*Governance and documentation responsibilities*

Lifecycle conclusions depend on traceable methods and assumptions. Anti-drug-antibody interpretation, for example, depends on assay sensitivity, drug tolerance, cut points, sampling, confirmatory strategy, and reporting quality [25]. An unqualified negative result cannot establish absence of immunogenicity.

Governance should also support consistent reasoning across functions and jurisdictions. International work on streamlined biosimilar development highlights the need for shared terminology, transparent expectations, and clearly assigned responsibilities [26]. Such recommendations do not constitute acceptance of one global lifecycle pathway.

LVCA assigns responsibility for five records: product knowledge, process-mechanism hypothesis, change-impact assessment, residual-uncertainty decision, and post-change update. Each should distinguish observations from interpretations and established evidence from proposed inference.

Governance must prevent both convenience-driven under-testing and automatic over-testing. Decision owners should be identifiable, while independent reviewers should challenge comparator selection, causal assumptions, assay sensitivity, model domain, evidence stopping, and monitoring plans.

*Limitations and research priorities*

The architecture is limited by the evidence used to populate it. A recent ustekinumab analysis argues that analytical data and single-dose pharmacokinetics may resolve comparable-immunogenicity questions in a specific context [27]. That conclusion requires testing across products, mechanisms, routes, populations, durations, and immune-risk profiles.

Model-based control presents additional limitations. Soft sensors depend on data quality, calibration, maintenance, transferability, interpretability, and stability of the underlying process [28]. A model may deteriorate while appearing technically operational if the reference process itself changes.

Decision-facing models should therefore be evaluated prospectively, temporally, across relevant sites or scales, and under known perturbations, missing-data conditions, and method changes. Small-data process monitoring remains especially vulnerable to overfitting and limited external validity [19].

Research should test whether LVCA improves detection of consequential change, reduces unsupported evidence escalation, avoids missed risk, and produces reproducible decisions. **Figure 2** summarizes the proposed pathway from manufacturing modification to bounded clinical assurance.




**Figure 2.** Change-Impact Pathway from Manufacturing Modification to Clinical Assurance.

## CONCLUSION

Biopharmaceutical lifecycle control should not be organized around permanent replication of historical manufacturing conditions or molecular distributions. The proposed LVCA instead connects heterogeneity, process understanding, critical quality attributes, longitudinal monitoring, comparability, change-impact reasoning, evidence escalation, clinical continuity, and governance within one traceable learning system. Its central claim is that assurance should depend on preservation of clinically relevant product and process relationships and resolution of change-specific uncertainty rather than manufacturing sameness alone. The acceptable variability envelope, drift construct, residual-uncertainty checkpoint, evidence-stopping record, clinical-continuity record, and integrated governance mechanism are original proposed contributions. Their usefulness remains dependent on product-specific mechanisms, sensitive analytical and functional methods, valid process models, appropriate clinical-pharmacology evidence, qualified immunogenicity assessment, and effective post-change learning. Prospective evaluation is required before the architecture can support scientific, manufacturing, clinical, or regulatory decisions.

**ACKNOWLEDGMENTS:** None

**CONFLICT OF INTEREST:** None

**FINANCIAL SUPPORT:** None

**ETHICS STATEMENT:** None

## REFERENCES

1. Wolff-Holz E, Tiitso K, Vleminckx C, Weise M. Evolution of the EU biosimilar framework: Past and future. BioDrugs. 2019;33(6):621-34. doi:10.1007/s40259-019-00377-y
2. Webster CJ, Wong AC, Woollett GR. An efficient development paradigm for biosimilars. BioDrugs. 2019;33(6):603-11. doi:10.1007/s40259-019-00371-4
3. Guillen E, Ekman N, Barry S, Weise M, Wolff-Holz E. A data driven approach to support tailored clinical programs for biosimilar monoclonal antibodies. Clin Pharmacol Ther. 2023;113(1):108-23. doi:10.1002/cpt.2785
4. Kim S, Song J, Park S, Ham S, Paek K, Kang M, et al. Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar. MAbs. 2017;9(4):704-14. doi:10.1080/19420862.2017.1305530
5. Goh JB, Ng SK. Impact of host cell line choice on glycan profile. Crit Rev Biotechnol. 2018;38(6):851-67. doi:10.1080/07388551.2017.1416577
6. Nimmerjahn F, Vidarsson G, Cragg MS. Effect of posttranslational modifications and subclass on IgG activity: From immunity to immunotherapy. Nat Immunol. 2023;24(8):1244-55. doi:10.1038/s41590-023-01544-8
7. Lee N, Lee JJ, Yang H, Baek S, Kim S, Kim S, et al. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab. MAbs. 2019;11(1):129-44. doi:10.1080/19420862.2018.1530920
8. Li Z, Du X, Wang YMC. A survey of FDA approved monoclonal antibodies and Fc-fusion proteins for manufacturing changes and comparability assessment. Pharm Res. 2024;41(1):13-27. doi:10.1007/s11095-023-03627-5
9. Nupur N, Chhabra N, Dash R, Rathore AS. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study. MAbs. 2018;10(1):143-58. doi:10.1080/19420862.2017.1402996
10. Schiestl M, Ranganna G, Watson K, Jung B, Roth K, Capsius B, et al. The path towards a tailored clinical biosimilar development. BioDrugs. 2020;34(3):297-306. doi:10.1007/s40259-020-00422-1
11. Kurki P, Kang HN, Ekman N, Knezevic I, Weise M, Wolff-Holz E. Regulatory evaluation of biosimilars: Refinement of principles based on the scientific evidence and clinical experience. BioDrugs. 2022;36(3):359-71. doi:10.1007/s40259-022-00533-x

12. Cohen HP, Turner M, McCabe D, Woollett GR. Future evolution of biosimilar development by application of current science and available evidence: The developer's perspective. BioDrugs. 2023;37(5):583-93. doi:10.1007/s40259-023-00619-0
13. Jiang M, Severson KA, Love JC, Madden H, Swann P, Zang L, et al. Opportunities and challenges of real-time release testing in biopharmaceutical manufacturing. Biotechnol Bioeng. 2017;114(11):2445-56. doi:10.1002/bit.26383
14. Wasalathanthri DP, Rehmann MS, Song Y, Gu Y, Mi L, Shao C, et al. Technology outlook for real-time quality attribute and process parameter monitoring in biopharmaceutical development—a review. Biotechnol Bioeng. 2020;117(10):3182-98. doi:10.1002/bit.27461
15. Luo S, Zhang B. Benchmark glycan profile of therapeutic monoclonal antibodies produced by mammalian cell expression systems. Pharm Res. 2024;41(1):29-37. doi:10.1007/s11095-023-03628-4
16. Webster CJ, Woollett GR. A 'global reference' comparator for biosimilar development. BioDrugs. 2017;31(4):279-86. doi:10.1007/s40259-017-0227-4
17. Li Z, Du X, Huang SM, Wang YMC. Pharmacokinetics-bridging between autoinjectors and prefilled syringes for subcutaneous injection: Case examples revealing a knowledge gap. Clin Pharmacol Ther. 2024;115(3):404-7. doi:10.1002/cpt.3145
18. Lee JAJ, Lee N, Seo YJ, Kim I. Consistency of product quality for SB5, an adalimumab biosimilar. BioDrugs. 2023;37(2):271-7. doi:10.1007/s40259-023-00581-x
19. Tulsyan A, Garvin C, Ündey C. Advances in industrial biopharmaceutical batch process monitoring: Machine-learning methods for small data problems. Biotechnol Bioeng. 2018;115(8):1915-24. doi:10.1002/bit.26605
20. Anupa A, Jesubalan NG, Trivedi R, Nitika N, Buddhiraju VS, Runkana V, et al. Implementation of machine learning tool for continued process verification of process chromatography unit operation. J Chromatogr A. 2025;1742:465642. doi:10.1016/j.chroma.2024.465642
21. Kirsch-Stefan N, Guillen E, Ekman N, Barry S, Knippel V, Killalea S, et al. Do the outcomes of clinical efficacy trials matter in regulatory decision-making for biosimilars? BioDrugs. 2023;37(6):855-71. doi:10.1007/s40259-023-00631-4
22. Sheikhy M, Schrieber SJ, Sun Q, Gershuny V, Matta MK, Bai JPF, et al. Considerations for use of pharmacodynamic biomarkers to support biosimilar development—(I) A randomized trial with PCSK9 inhibitors. Clin Pharmacol Ther. 2023;113(1):71-9. doi:10.1002/cpt.2769
23. Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: A systematic review. Clin Pharmacol Ther. 2020;108(4):734-55. doi:10.1002/cpt.1836
24. Barbier L, Vulto AG. Interchangeability of biosimilars: Overcoming the final hurdles. Drugs. 2021;81(16):1897-903. doi:10.1007/s40265-021-01629-4
25. Myler H, Pedras-Vasconcelos J, Phillips K, Hottenstein CS, Chamberlain P, Devanaryan V, et al. Anti-drug antibody validation testing and reporting harmonization. AAPS J. 2022;24(1):4. doi:10.1208/s12248-021-00649-y
26. Car E, Barbier L, Schwarzenberger I, Huys I, Simoens S, Vulto AG. Toward regulatory convergence and streamlined biosimilar development: Recommendations from an international qualitative study. BioDrugs. 2025;39(6):943-55. doi:10.1007/s40259-025-00746-w
27. Schiestl M, Roy N, Trieb M, Park JP, Guillen E, Woollett G, et al. Analytical data and single-dose PK are sufficient to conclude comparable immunogenicity for biosimilars: An ustekinumab case study. BioDrugs. 2025;39(5):769-76. doi:10.1007/s40259-025-00733-1
28. Brunner V, Siegl M, Geier D, Becker T. Challenges in the development of soft sensors for bioprocesses: A critical review. Front Bioeng Biotechnol. 2021;9:722202. doi:10.3389/fbioe.2021.722202